Paper Information

Title: 

MASS PRODUCTION OF PURE ANTI-DIGOXIN MONOCLONAL ANTIBODY FOR IMMUNOTHERAPY

Type: SPEECH
Author(s): GOLMAKANY N.,RASAEI M.J.,FOROUZANDEH M.,SHOJA ALSADATI S.A.
 
 
 
Name of Seminar: IRANIAN CONGRESS OF TOXICOLOGY
Type of Seminar:  CONGRESS
Sponsor:  SOCIETY OF TOXICOLOGY
Date:  2004Volume 8
 
 
Abstract: 

Cardiac glycoside, digoxin, has been played a prominent role in therapy of congestive heart failure and supraventicular tachycardia over two centuries. Digoxin intoxication is a serious and frequently encountered clinical condition due to massive ingestion often suicide intent or in patient with sever underlying cardiac disease. Since no specific antagonist of digoxin has yet been described, using specific antibodies especially monoclonal antibodies for reversal digoxin toxicity have been preferred.
Currently, MAbs top other biopharmaceutical drugs as actual products on the market. In recent years much effort and investment has been made to exploit large scale cell culture science and technology to manufacture the pharmaceutical products.
To support hybridoma cell growth for producing MAbs, a lot of processing required. One processing is the adaptation and optimisation of cell growth in bioreactors.
Due to increasing need of anti-digoxin monoclonal antibodies in immunotherapy, we aimed to mass production of this cell line for manufacture of antibody. In this study, we exerted two modifications in membrane- based cell culture system that yielded 1.4 mg/ml pure MAb during sever days without down-stream processing. The product in addition to purity was sterile that may be used for in vivo assays or immunotherapy in animal models.

 
Keyword(s): 
 
Yearly Visit 24   tarjomyar
 
Latest on Blog
Enter SID Blog